CD8A and neoplasm: Evidence revealed that cDC1s in the TME play pivotal roles in the priming and expansion of tumor-specific CD8+ T cells17–22, promoting their infiltration into the TME23, and thus enhancing the efficacy of anti-PD-1 therapy24–26.